# Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion

> **NCT00969293** · PHASE1 · TERMINATED · sponsor: **Fovea Pharmaceuticals SA** · enrollment: 11 (actual)

## Conditions studied

- Macular Edema
- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** FOV2302 (Ecallantide)

## Key facts

- **NCT ID:** NCT00969293
- **Lead sponsor:** Fovea Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2011-07
- **Final completion:** 2012-03
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2012-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00969293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00969293, "Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT00969293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*